Biomea Fusion Inc

NASDAQ BMEA

Data sourced from

and

Download Data

Biomea Fusion Inc Cost of Revenue 1 year YoY Change (%) for the quarter ending March 31, 2024: -53.59%

Biomea Fusion Inc Cost of Revenue 1 year YoY Change (%) is -53.59% for the quarter ending March 31, 2024. Cost of Revenue refers to the expenses directly associated with producing or delivering the goods or services sold by a company. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Biomea Fusion Inc Cost of Revenue for the quarter ending March 31, 2023 was USD 905.00 K.

NASDAQ: BMEA

Biomea Fusion Inc

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road, Redwood City, CA, United States, 94063
Employees	110
Sector	Healthcare
Industry	Biotechnology

Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends